Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria
Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria Original Story PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, provides an update on recent exchanges with [...]